Prospects for prevention and treatment of vascular cognitive impairment

Current Opinion in Investigational Drugs

Volumn 4, Issue 9, 2003, Pages 1082-1087

  Di Legge, Silvia ^a   Hachinski, Vladimir ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Aggressive treatment; Cerebrovascular disease; Dementia; Secondary prevention; Vascular cognitive impairment; Vascular risk factors

Indexed keywords

AMYLOID; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL;

AGING; ALZHEIMER DISEASE; BLOOD PRESSURE REGULATION; BRAIN ATROPHY; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; DRUG TARGETING; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK FACTOR; STROKE; WHITE MATTER;

AGING; BRAIN; CLINICAL TRIALS; COGNITION DISORDERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAGNETIC RESONANCE IMAGING; RISK FACTORS; VASCULAR DISEASES;

EID: 0142245363     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, McDowell I: Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet (1997) 349(9068):1793-1796.
2. Tatemichi TK, Paik M, Bagiella E, Desmond DW, Stern Y, Sano M, Hauser WA, Mayeux R: Risk of dementia after stroke in a hospitalized cohort: Results of a longitudinal study. Neurology (1994) 44(10):1885-1891.
3. Censori B, Manara O, Agostinis C, Camerlingo M, Casto L, Galavotti B, Partziguian T, Servalli MC, Cesana B, Belloni G, Mamoli A: Dementia after first stroke. Stroke (1996) 27(7):1205-1210.
4. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M: Clinical determinants of poststroke dementia. Stroke (1998) 29(1):75-81.
5. Hachinski VC, Lassen NA, Marshall J: Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet (1974) 2(7874):207-210.
6. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A et al.: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 43(2):250-260.
7. Braak H, Braak E: Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol (1991) 1(3):213-216.
8. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM: Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960-1984). Neurology (1996) 46(1):154-159.
9. Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D: Poststroke dementia: Incidence and relationship to prestroke cognitive decline. Neurology (2001) 57(7):1216-1222
10. Kalaria RN: Small vessel disease and Alzheimer's dementia: Pathological considerations. Cerebrovasc Dis (2002) 13(Suppl 2):48-52.
11. Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, Miklossy J: Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke (2002) 33(8):1986-1992.
12. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. J Am Med Assoc (1997) 277(10):813-817. This autopsy-confirmed study underlined the role of cerebrovascular lesions in the clinical expression of AD dementia. The possibility that vascular lesions trigger and enhance the deposition of clinically significant AD pathology is suggested.
13. Barba R, Castro MD, Del Mar Morin M, Rodriguez-Romero R, Rodriguez-Garcia E, Canton R, Del Ser T: Prestroke dementia. Cerebrovasc Dis (2001) 11(3):216-224.
14. De La Torre JC: Alzheimer's disease: How does it start? J Alzheimers Dis (2002) 4(6):497-512.
15. Hachinski V: Vascular dementia: A radical redefinition. Dementia (1994) 5(3-4):130-132.
16. Bowler JV, Hachinski V: Vascular Cognitive Impairment. Preventable Dementia. Oxford University Press, Oxford, UK (2003). This book presents the full scope of VCl, with updates that reflect the most current thinking, providing future perspectives for clinical and preclinical studies.
17. Hachinski V: Preventable senility: A call for action against the vascular dementias. Lancet (1992) 340(8820):645-648.
18. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V: The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med (1997) 337(23):1667-1674.
19. Bowler JV, Steenhuis R, Hachinski V: Conceptual background to vascular cognitive impairment. Alzheimer Dis Assoc Disord (1999) 13(Suppl 3):30-37.
20. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I: Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology (2000) 54(2):447-451.
21. Pantoni L, Leys D, Fazekas F, Longstreth Jr. WT, Inzitari D, Wallin A, Filippi M, Scheltens P, Erkinjuntti T, Hachinski V: Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord (1999) 13(Suppl 3):49-54.
22. Pohjasvaara T, Mantyla R, Salonen O, Aronen HJ, Ylikoski R, Hietanen M, Kaste M, Erkinjuntti T: MRI correlates of dementia after first clinical ischemic stroke. J Neurol Sci (2000) 181(1-2):111-117.
23. Meyer JS, Xu G, Thornby J, Chowdhury MH, Quach M: Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease? Stroke (2002) 33(8):1981-1985.
24. Vermeer SE, Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Breteler MM: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med (2003) 348(13):1215-1222. The authors describe a higher occurrence of decline in cognitive fucntions in elderly people with additional clinically silent lesions in the population-based Rotterdam Scan Study.
25. Mungas D, Reed BR, Jagust WJ, DeCarli C, Mack WJ, Kramer JH, Weiner MW, Schuff N, Chui HC: Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology (2002) 59(6):867-873.
26. Manolio TA, Olson J, Longstreth WT: Hypertension and cognitive function: Pathophysiologic effects of hypertension on the brain. Curr Hypertens Rep (2003) 5(3):255-261.
27. DeCarli C: The role of cerebrovascular disease in dementia. Neurology (2003) 9(3):123-126.
28. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A: 15-Year longitudinal study of blood pressure and dementia. Lancet (1996) 347(9009):1141-1145.
29. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ: Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging (2000) 21(1):49-55.
30. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ: Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS. Honolulu-Asia aging Study. Neurobiol Aging (2000) 21(1):57-62.
31. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. Br Med J (2001) 322(7300):1447-1451. The autors provide further insight into the role of vascular risk factors in accelerating AD dementia, suggesting an overlap between the vascular and degenerative processes on pathophysiological and clinical grounds.
32. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, Van Harskamp F, Van Duijn CN, Van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet (1997) 349(9046):151-154.
33. Ott A, Breteler MM, De Bruyne MC, Van Harskamp F, Grobbee DE, Hofman A: Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke (1997) 28(2):316-321.
34. Kilander L, Andren B, Nyman H, Lind L, Boberg M, Lithell H: Atrial fibrillation is an independent determinant of low cognitive function: A cross-sectional study in elderly men. Stroke (1998) 29(9):1816-1820.
35. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ: Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol (1997) 145(4):301-308.
36. Ott A, Stolk RP, Van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology (1999) 53(9):1937-1942.
37. MacKnight C, Rockwood K, Awalt E, McDowell I: Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord (2002) 14(2):77-83.
38. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, D'Agostino RB, Wolf PA: Plasma total cholesterol level as a risk factor for Alzheimer's disease: The Framingham Study. Arch Intern Med (2003) 163(9):1053-1057.
39. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I: Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol (2002) 156(5):445-453.
40. Luchsinger JA, Tang MX, Shea S, Mayeux R: Caloric intake and the risk of Alzheimer disease. Arch Neurol (2002) 59(8):1258-1263.
41. Ruitenberg A, Van Swieten JC, Witteman JC, Mehta KM, Van Duijn CM, Hofman A, Breteler MM: Alcohol consumption and risk of dementia: The Rotterdam Study. Lancet (2002) 359(9303):281-286.
42. Ott A, Slooter AJ, Hofman A, Van Harskamp F, Witteman JC, Van Broekhoven C, Van Duijn CM, Breteler MM: Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam Study. Lancet (1998) 351(9119):1840-1843.
43. Wang HX, Fratiglioni L, Frisoni GB, Viitanen M, Winblad B: Smoking and the occurrence of Alzheimer's disease: Cross-sectional and longitudinal data in a population-based study. Am J Epidemiol (1999) 149(7):640-644.
44. Tyas SL, White LR, Petrovitch H, Webster Ross G, Foley DJ, Heimovitz HK, Launer LJ: Mid-life smoking and late-life dementia: The Honolulu-Asia Aging Study. Neurobiol Aging (2003) 24(4):589-596.
45. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T et al.: Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet (1998) 352(1937):1347-1351.
46. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z et al.: The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med (2002) 162(18):2046-2052. The European randomized, placebo-controlled trial described in this paper reinforced the evidence for the efficacy of blood pressure control in preservation of cognitive in the elderly at up to four years of follow-up.
47. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J, The PROGRESS Collaborative Group: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med (2003) 163(9):1069-1075.
48. Murray MD, Lane KA, Gao S, Evans RM, Unverzagt FW, Hall KS, Hendrie H: Preservation of cognitive function with antihypertensive medications: A longitudinal analysis of a community-based sample of African Americans. Arch Intern Med (2002) 162(18):2090-2096.
49. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, For the SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens (2003) 21(5):875-886.
50. Di Bari M, Pahor M, Franse LV, Shorr RI, Wan JY, Ferrucci L, Somes GW, Applegate WB: Dementia and disability outcomes in large hypertension trials: Lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol (2001) 153(1):72-78.
51. Ratnasabapathy Y, Anderson CA, Tzurio C, Jones M: Predicting dementia in patients with cerebrovascular disease: Results from PROGRESS. Cerebrovascular Dis (2003) 16(Suppl 4):8.
52. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet (2000) 356(9242):1627-1631. This paper demonstrated an association between the use of statins and a reduced risk of developing dementia. The possible effects of statins on the cerebral microvasculature, other than through lipid lowering, are discussed.
53. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: A randomised placebo-controlled trial. Lancet (2002) 360(9326):7-22.
54. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet (2002) 260(9346):1623-1630.
55. Etminan M, Gill S, Samii A: The role of lipid-lowering drugs in cognitive function: A meta-analysis of observational studies. Pharmacotherapy (2003) 23(6):726-730.
56. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM: Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy (2003) 23(7):871-880.
57. Danesh FR, Anel RL, Zeng L, Lomasney J, Sahai A, Kanwar YS: Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz) (2003) 51(3):139-148.
58. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL: Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation (2003) 108(4):426-431.
59. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, Ucchino S, Spigonardo F, Bajocchi G, Bei R, Muraro R et al.: Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation (2003) 107(11):1479-1485.
60. Henon H, Dureiu I, Lebert F, Pasquier F, Leys D: Influence of prestroke dementia on early and delayed mortality in stroke patients. J Neurol (2003) 250(1):10-16.
61. Salas M, In't Veld BA, Van Der Linden PD, Hofman A, Breteler M, Stricker BH: Impaired cognitive function and compliance with antihypertensive drugs in elderly: The Rotterdam Study. Clin Pharmacol Ther (2001) 70(6):561-566.
62. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M: Use of lipid-lowering drugs in older adults with and without dementia: A community-based epidemiological study. J Am Geriatr Soc (2002) 50(11):1852-1856.
63. Walters RJL, Fox NC, Schott JM, Crum WR, Stevens JM, Rossor MN, Thomas DJ: Transient ischaemic attacks are associated with increased rates of global cerebral atrophy. J Neurol Neurosurg Psychiatry (2003) 74(2):213-216.
64. Kumar V, Anand R, Messina J, Hartman R, Veach J: An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol (2000) 7(2):159-169.
65. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet (2002) 359(9314):1283-1290.
66. Meyer JS, Chowdhury MH, Xu G, Li YS, Quach M: Donepezil treatment of vascular dementia. Ann NY Acad Sci (2002) 977:482-486.
67. Sun MK, Alkon DL: Depressed or demented: Common CNS drug targets? Curr Drug Target CNS Neurol Disord (2002) 1(6):575-592.
68. Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C, Van Duijn CM: Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study. Arch Neurol (1998) 55(7):964-968.
69. Saunders AM, Roses AD: Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. Stroke (1993) 24(9):1416-1417.
70. Olichney JM, Hansen LA, Hofstetter CR, Lee JH, Katzman R, Thal LJ: Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. Arch Neurol (2000) 57(6):869-874.
71. Johnston JM, Nazar-Stewart V, Kelsey SF, Kamboh MI, Ganguli M: Relationships between cerebrovascular events, apoE polymorphism and Alzheimer's disease in a community sample. Neuroepidemiology (2000) 19(6):320-326.
72. Slooter AJ, Cruts M, Ott A, Bots ML, Witteman JC, Hofman A, Van Broeckhoven C, Breteler MM, Van Duijn CM: The effect of apoE on dementia is not through atherosclerosis: The Rotterdam Study. Neurology (1999) 53(7):1593-1595.
73. Prince M, Lovestone S, Cervilla J, Joels S, Powell J, Russ C, Mann A: The association between apoE and dementia does not seem to be mediated by vascular factors. Neurology (2000) 54(2):397-402.
74. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H: Apolipoprotein Eε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med (2002) 137(3):149-155.
75. Cedazo-Minguez A, Cowburn RF: Apolipoprotein E: A major piece in the Alzheimer's disease puzzle. J Cell Mol Med (2001) 5(3):254-266.
76. 40 and apoE immunostaining of plaques in fatal head injury. Neuropathol Appl Neurobiol (2000) 26(2):124-132.
77. Teasdale GM, Nicoll JA, Murray G, Fiddes M: Association of apolipoprotein E polymorphism with outcome after head injury. Lancet (1997) 350(9084):1069-1071.
78. McCarron MO, Muir KW, Weir CJ, Dyker AG, Bone I, Nicoll JA, Lees KR: The apolipoprotein Eε4 allele and outcome in cerebrovascular disease. Stroke (1998) 29(9):1882-1887.
79. Buttini M, Akeefe H, Lin C, Mahley RW, Pitas RE, Wyss-Coray T, Mucke L: Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience (2000) 97(2):207-210.
80. Guo Z, Fratiglioni L, Viitanen M, Lannfelt L, Basun H, Fastbom J, Winblad B: Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: Variation by use of antihypertensive medication? Am J Epidemiol (2001) 153(3):225-231.
81. Willett WC: Balancing life-style and genomics research for disease prevention. Science (2002) 296(5568):695-698.
82. Wardlaw JM, Sandercock PA, Dennis MS, Starr J: Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke (2003) 34(3):806-812. In this paper the authors presented valuable thought on the possible role played by abnormal functioning of the blood-brain barrier in progressive cognitive decline and dementia in individuals affected by diffuse white matter changes and lacunar infarctions.
83. 6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord (2003) 16(3):145-150.
84. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP: Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke (2002) 33(10):2351-2356.
85. Bodor N, Buchwald P: Barriers to remember: Brain-targeting chemical delivery systems and Alzheimer's disease. Drug Disc Today (2002) 7(14):766-774.
86. Adessi C, Frossard MJ, Boissard C, Fraga S, Bieler S, Ruckle T, Villbois F, Robinson SM, Mutter M, Banks WA, Soto C: Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem (2003) 278(16):13905-13911.